Aclarion Inc Stock Price, News & Analysis

Aclarion, Inc. (Nasdaq: ACON) has announced its first commercial agreement in Michigan with Sheridan Community Hospital. This agreement brings Nociscan, Aclarion's innovative solution for identifying chronic low back pain, to central Michigan and to Dr. John Keller, a leading neurosurgeon and Aclarion medical advisor.

Nociscan is the first evidence-supported SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. It objectively quantifies chemical biomarkers associated with disc pain, providing critical insights when used with other diagnostic tools.

This agreement is part of Aclarion's strategy to expand access to Nociscan in the US market, following recent insurance coverage announcements in the UK. It represents a step towards potential payer coverage in the United States.

Aclarion (NASDAQ: ACON) has achieved a significant milestone by securing coverage for its Nociscan technology from Vitality, the third major private health insurer in the UK. This addition means Aclarion now has coverage from 3 of the 4 largest private health insurers in the UK, providing access to nearly 60% of patients with private health insurance in the Greater London market.

Nociscan, a SaaS platform that helps physicians identify the location of chronic low back pain, is gaining traction in the UK healthcare market. The London Clinic, a renowned independent hospital, has played a important role in demonstrating Nociscan's value and securing payer coverage. Aclarion's CEO, Brent Ness, expects this success to be replicated across their 10 KOL sites globally.

With private medical insurance becoming increasingly popular in the UK, these coverage decisions represent a significant shift in Aclarion's business model, providing a clear path to commercialization in the UK market.

Aclarion achieved a significant milestone with Aviva, a top UK private medical insurer, covering Nociscan, its AI-driven diagnostic tool for chronic low back pain. This coverage extends Nociscan's availability to 45% of patients with private insurance in Greater London, joining AXA, which already provides coverage. This development marks a important step in gaining broader market adoption and potential value creation for Aclarion. Nociscan, the first evidence-supported SaaS platform, helps physicians noninvasively identify painful lumbar discs by quantifying chemical biomarkers. The London Clinic is among the premier institutions adopting this technology.

Aclarion (Nasdaq: ACON) announced the first payer coverage of its Nociscan technology by AXA in Greater London, UK, in cooperation with The London Clinic. AXA, the second largest provider of private medical insurance in the UK, covers about 30% of the private medical insurance market with around 3 million insured clients. This endorsement marks a significant milestone for Aclarion, paving the way for widescale commercialization and broader adoption of Nociscan, a tool designed to assist physicians in diagnosing chronic low back pain. The decision is expected to improve patient outcomes significantly and drive future revenue growth for Aclarion.

Aclarion has extended its commercial agreement with The London Clinic to increase the use of Nociscan, a technology that helps identify the location of chronic low back pain. The new contract sets a higher price for Nociscan and includes efforts to secure payer coverage from private health insurers. The London Clinic, a renowned private hospital, will also work to expand access to Nociscan for patients and referring physicians throughout Greater London. The extension follows compelling results from an initial evaluation involving 20 patients. CEO Brent Ness highlighted the importance of the UK market and expressed confidence in achieving similar results in the U.S. market.